Cabergoline versus Coasting in the Prevention of Ovarian Hyperstimulation Syndrome and Assisted Reproductive Technologies Outcome in High Risk Patients

Authors

  • Maryam Bagheri
  • Mina Jafarabadi
  • Soheila Ansaripour
Abstract:

Background Coasting is the most common method used in the prevention of ovarian hyperstimulation syndrome (OHSS) acting through vascular endothelial growth factor (VEGF) reduction. However, the pregnancy rate is reported to fall with coasting when it takes more than three days. Recently lowdose cabergoline, a selective D2 dopamine receptor agonist has been proven to selectively reduce vascular permeability without affecting angiogenesis and seems to be able to decrease the rate of OHSS without affecting pregnancy rate. MaterialsAndMethods This clinical trial was performed on 60 women in assisted reproductive technologies (ART) cycles at risk of OHSS, having at least 20 follicles in their ovaries (mostly ≤14mm) and a serum estradiol level ≥3000pg/mL. Patients were divided into two equal groups. In group A, oral cabergoline 0.5 mg/day was given for seven days after hCG administration; while in group B gonadotropin administration was halted until serum estradiol levels reached less than 3000pg/mL before hCG administration. The main outcome measurements compared were rates of pregnancy and severity of OHSS. Results Total number of oocytes, metaphase II oocytes, fertilization and clinical pregnancy rates were higher in group A (p

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients

background: coasting is the most common method used in the prevention of ovarian hyperstimulation syndrome (ohss) acting through vascular endothelial growth factor (vegf) reduction. however, the pregnancy rate is reported to fall with coasting when it takes more than three days. recently lowdose cabergoline, a selective d2 dopamine receptor agonist has been proven to selectively reduce vascular...

full text

The Effectiveness of Cabergoline for the Prevention of Ovarian Hyperstimulation Syndrome

Type 2 receptors for vascular endothelial growth factor are believed to be involved in the pathophysiology of ovarian hyperstimulation syndrome (OHSS). The objective of this study was to examine the preventive effects of cabergoline on OHSS and its complications. The study is a non randomized clinical trial conducted in 2006-2008 on 75 patients, which were at risk of OHSS and underwent assisted...

full text

Comparison of Cabergoline with Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection:A randomized trial

a:4:{s:9:"Objective";s:192:"The aim of the present study was to compare Quinagolide with Cabergoline in prevention of ovarian hyper stimulation syndrome among high risk women undergoing intra cytoplasmic sperm injection.";s:19:"MaterialsAndMethods";s:948:"Material and Methods: This Randomized clinical trial study was performed from March 2015 to February 2017. One hundred and twenty six women u...

full text

comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study

background:   objective: comparison of albumin and cabergoline in the prevention of ohss.   materials and methods: 95 high risk infertile women for ohss (more than 20 follicles in both ovaries at day of human chorionic gonadotropin (hcg) injection) were randomly divided into two groups. first group including 48 women received 10 unit intravenous albumin at starting oocyte retrieval, and second ...

full text

Effect of Low-dose Human Chorionic Gonadotropin on the Prevention of Ovarian Hyperstimulation Syndrome and in Vitro Fertilization Outcome

Background & aim: Ovarian hyperstimulation syndrome (OHSS) is a rare but most potentially life-threatening disorder in women under in vitro fertilization (IVF). This study aimed to determine the effect of low-dose human chorionic gonadotropin (hCG) on the prevention of OHSS and IVF outcome. Methods: This single-blind non-randomized clinical trial was performed from October 2008 to November 2012...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 3  issue 1

pages  35- 40

publication date 2009-03-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023